Calcitonin, Osteocalcin and Osteopontin in Lung Cancer

Main Article Content

Yu.V. Dumanskyi
V.A. Stepko
O.V. Syniachenko
H.S. Taktashov
O.A. Homozova


ackground. Lung cancer markers are low levels of the hormone calcitonin in the blood, and high levels of proteins osteocalcin and osteopontin, connected to each other, reflect the processes of bone metastasis and have a predictive value. Objective: to evaluate blood levels of calcitonin, osteocalcin and osteopontin, the factors determining them, the nature of relationships and prognostic role in bone metastasis at different variants of lung cancer. Materials and methods. The study included 86 patients with lung cancer aged 24 to 80 years (mean 58 years), among whom there were 84 % of men and 16 % of women. Central lung cancer occurred in 81 % of cases, peripheral — in 19 %. Small-cell lung cancer has been detected in 21 % of patients, non-small-cell — in 79 %, including adenocarcinoma — in 38 %, squamous-cell carcinoma — in 35 %, large-cell carcinoma — in 6 %. IIIA stage of neoplastic process was noted in 12 % of cases, IIIB — in 21 %, IV — in 67 %. Results. Lung cancer is accompanied by a decrease of bone-related hormone calcitonin in the blood of 20 % of patients on the background of increased concentrations of tumor markers osteocalcin and osteopontin (in 76 and 79 % of cases, respectively), which is closely associated with morphological variant (small- and non-small-cell), the stage and severity of pathological process, determines the development of compression syndrome, tumor invasion into the chest wall, metastasis in lymph nodes and bones, occurrence of chemoradiotherapy complications in the form of radiation pulmonary fibrosis, pulmonary hypertension and myelodepression, and indicators of osteocalcin- and osteopontinemia are inversely correlated with the duration of life of patients. Conclusions. In lung cancer, calcitonin, osteocalcin and osteopontin are the markers of the severity of the disease, reflect the metastasis of the tumor process in the skeleton and have a predictive value.

Article Details

How to Cite
Dumanskyi, Y., V. Stepko, O. Syniachenko, H. Taktashov, and O. Homozova. “Calcitonin, Osteocalcin and Osteopontin in Lung Cancer”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 4.76, Aug. 2016, pp. 26-30, doi:10.22141/2224-0721.4.76.2016.77795.
Original Researches


Avrillon V, Locatelli-Sanchez M, Folliet L, Carbonnaux M, Perino E, Fossard G, Desseigne M, Freymond N, Geriniere L, Perrot E, Souquet PJ, Couraud S. Lung cancer may increase serum procalcitonin level. Infect Disord Drug Targets 2015;15(1):57-63. doi: 10.1016/j.bbrc.2015.01.097.

Ayan AK, Erdemci B, Orsal E, Bayraktutan Z, Akpinar E, Topcu A, Turkeli M, Seven B. Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis? Rev Esp Med Nucl Imagen Mol 2015;27(10):182-8. doi: 10.1016/j.remn.2015.09.002.

Bauer NB, Khassawna TE, Goldmann F, Stirn M, Ledieu D, Schlewitz G, Govindarajan P, Zahner D, Weisweiler D, Schliefke N, Böcker W, Schnettler R, Heiss C, Moritz A. Characterization of bone turnover and energy metabolism in a rat model of primary and secondary osteoporosis. Exp Toxicol Pathol 2015;67(4):287-96. doi: 10.1016/j.etp.2015.01.004.

Buckens CF, van der Graaf Y, Verkooijen HM, Mali WP, Isgum I, Mol CP, Verhaar HJ, Vliegenthart R, Oudkerk M, van Aalst CM, de Koning HJ, de Jong PA. Osteoporosis markers on low-dose lung cancer screening chest computed tomography scans predict all-cause mortality. Eur Radiol 2015;25(1):132-9. doi: 10.1007/s00330-014-3361-0.

Ceniceros L, Aristu J, Castanon E, Rolfo C, Legaspi J, Olarte A, Valtuena G, Moreno M, Gil-Bazo I. Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients. Clin Transl Oncol 2015;55(8):213-9. doi: 10.1007/s12094-015-1361-4.

Grаdalska-Lampart M, Karczmarek-Borowska B, Radziszewska AU. Lung cancer in Podkarpackie region in the years 2002-2011. Pneumonol Alergol Pol 2015;83(2):109-19.

Kang Y. Imaging TGFβ signaling in mouse models of cancer metastasis. Methods Mol Biol 2016;1344:219-32. doi: 10.5603/PiAP.2015.0018.

Klahan S, Kuo CN, Chien SC, Lin YW, Lin CY, Lin CH, Chang WC, Lin CI, Hung KS, Chang WP. Osteoporosis increases subsequent risk of gallstone: a nationwide population-based cohort study in Taiwan. BMC Gastroenterol 2014;18(14):192-9. doi: 10.1186/s12876-014-0192-z.

Kukulj S, Popovic F, Budimir B, Drpa G, Serdarevic M, Polic-Vizintin M. Smoking behaviors and lung cancer epidemiology: a cohort study. Psychiatr Danub 2014;26(3):485-9.

Li X, Bie Z, Zhang Z, Li Y, Hu X, Liu W, Zhang S, Cheng G, Ai B. Clinical analysis of 64 patients with lung-cancer-associated hypercalcemia. J Cancer Res Ther 2015;11:275-9.

Patout M, Salaün M, Brunel V, Bota S, Cauliez B, Thiberville L. Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem 2014;47(18):263-7. doi: 10.1016/j.clinbiochem.2014.09.002.

Peng B, Wang YH, Huang Z, Feng SJ, Wang YS. Prognostic significance of osteopontin in patients with lung cancer: a meta-analysis. Int J Clin Exp Med 2014;7(12):4616-26.

Pilotto S, Carbognin L, Karachaliou N, Garassino M, Cuppone F, Petraglia S, Rosell R, Tortora G, Bria E. Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Transl Lung Cancer Res 2015;4(6):704-12. doi: 10.3978/j.issn.2218-6751.2015.10.08.

Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Glüer CC, Kendler D, Napoli N, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, de Villiers TJ, El Hajj Fuleihan G. Cancer-associated bone disease. Osteoporos Int 2013;24(12):2929-53. doi: 10.1007/s00198-013-2530-3.

Sun B, Zhang Z. Advances in research of osteopontion and its receptor CD44v in tumor invasion and metastasis. Zhongguo Fei Ai Za Zhi 2015;18(11):714-7. doi: 10.3779/j.issn.1009-3419.2015.11.11.

Wang H, Zhuo Y, Hu X, Shen W, Zhang Y, Chu T. CD147 deficiency blocks IL-8 secretion and inhibits lung cancer-induced osteoclastogenesis. Biochem Biophys Res Commun 2015;458(2):268-73. doi: 10.1016/j.bbrc.2015.01.097.

Wisinski KB, Ledesma WM, Kolesar J, Wilding G, Liu G, Douglas J, Traynor AM, Albertini M, Mulkerin D, Bailey HH. A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 2014;11(1):125-32. doi: 10.1177/1078155214541572.

Most read articles by the same author(s)